Pfizer Inc (PFE): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Pfizer ( PFE) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.1%. By the end of trading, Pfizer fell 41 cents (-1.6%) to $25.19 on average volume. Throughout the day, 27.2 million shares of Pfizer exchanged hands as compared to its average daily volume of 28.5 million shares. The stock ranged in price between $25.02-$25.36 after having opened the day at $25.30 as compared to the previous trading day's close of $25.60. Other companies within the Drugs industry that declined today were: ADVENTRX Pharmaceuticals ( ANX), down 10.2%, Keryx Biopharmaceuticals ( KERX), down 9.4%, Cormedix ( CRMD), down 9.1%, and OxiGene ( OXGN), down 6.9%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. Pfizer has a market cap of $192.41 billion and is part of the health care sector. The company has a P/E ratio of 21.8, above the average drugs industry P/E ratio of 19.1 and above the S&P 500 P/E ratio of 17.7. Shares are up 19% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate Pfizer a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Telik ( TELK), up 9.3%, Reliv' International ( RELV), up 6.4%, Aegerion Pharmaceuticals ( AEGR), up 5.5%, and Medgenics ( MDGN), up 5%, were all gainers within the drugs industry with Jazz Pharmaceuticals ( JAZZ) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux